Bronchiolitis

Overview and Epidemiology

Bronchiolitis is an acute viral lower respiratory tract infection causing inflammation and obstruction of the small airways (bronchioles). It is the single leading cause of infant hospitalization in the United States, with 544,828 weighted hospital discharges across just four national survey years (2000, 2003, 2006 and 2009) in children under two years of age (Hasegawa et al., Pediatrics 2013), and generating roughly 2.1 million outpatient and emergency department visits annually. The hospitalization rate fell from 17.9 to 13.5 per 1,000 person-years between 2000 and 2016 (Fujiogi et al., Pediatrics 2019). Between 2000 and 2009 the share of hospitalized children with high-risk conditions rose from 5.9% to 7.9%, and use of mechanical ventilation rose from 1.9% to 2.3% (Hasegawa et al.).

The condition is caused by a range of respiratory viruses, not a single pathogen:

• Respiratory syncytial virus (RSV): The dominant cause, responsible for 50–75% of bronchiolitis cases. Respiratory syncytial virus has two circulating antigenic subtypes (A and B) and follows a predictable winter epidemic pattern in temperate climates.
• Rhinovirus: The second most common cause, accounting for 20–30% of cases. Rhinovirus-associated bronchiolitis tends to be less severe overall but peaks in autumn and spring, extending the season beyond respiratory syncytial virus's winter dominance.
• Human metapneumovirus (hMPV): Responsible for approximately 5–10% of cases; clinically similar to respiratory syncytial virus bronchiolitis and peaks in late winter and early spring.
• Parainfluenza viruses (types 1–3): Contribute a smaller but notable proportion; type 3 in particular can cause bronchiolitis in very young infants.
• Adenovirus, bocavirus, coronavirus, influenza: Less frequent but recognized causes, especially in immunocompromised or hospitalized children.

Peak vulnerability occurs between 2 and 6 months of age, when maternally derived antibody wanes and the infant's own immune system remains immature. The disease is uncommon after 24 months of age because larger airway caliber blunts the obstructive impact of mucosal edema. Seasonality in the Northern Hemisphere runs from November through March, with respiratory syncytial virus epidemics peaking in December–January.

Back to Table of Contents

Pathophysiology

Bronchiolitis results from a cascade of viral-driven injury to the small conducting airways rather than from true bronchospasm, a distinction that directly explains why bronchodilators fail.

The sequence of events:

1. Viral inoculation and replication: Inhaled virus attaches to apical ciliated columnar epithelial cells of the bronchioles. Respiratory syncytial virus uses the G protein to bind the CX3CR1 receptor on ciliated airway cells, shown in human airway cell cultures and in mice (Johnson et al., PLoS Pathogens 2015), and other surface receptors; rhinovirus uses ICAM-1 on lower airway epithelium. Replication occurs rapidly within 1–2 days of exposure.
2. Epithelial necrosis and sloughing: Infected cells undergo necrosis and apoptosis. Ciliated epithelium is destroyed, impairing mucociliary clearance and depositing cellular debris into the bronchiolar lumen.
3. Peribronchiolar inflammation: Innate immune activation triggers mast cell degranulation and recruitment of neutrophils and lymphocytes into the airway wall and submucosa, causing pronounced mucosal edema.
4. Luminal obstruction: The combination of sloughed epithelium, inflammatory exudate, excess mucus production, and edematous walls dramatically narrows the lumen of airways that are already only 1–2 mm in diameter. Small absolute reductions in radius cause disproportionately large increases in resistance (Poiseuille's law: resistance ∝ 1/r⁴).
5. Air trapping and atelectasis: Partial obstruction acts as a check-valve, allowing air in on inhalation (when airways dilate) but preventing it from exiting on exhalation (when airways narrow). This creates distal air trapping and hyperinflation. Complete obstruction leads to resorption atelectasis of distal alveoli. Both processes coexist in the same lung, often in adjacent segments.
6. Ventilation-perfusion (V/Q) mismatch: Atelectatic segments receive perfusion but no ventilation (shunt), while hyperinflated regions are ventilated but overstretched and poorly perfused (dead space). The resulting V/Q mismatch drives hypoxemia and, in severe cases, hypercapnia as the infant's respiratory muscles fatigue.

Because the obstruction is mechanical — not smooth-muscle mediated — inhaled beta-2 agonists (albuterol) cannot reverse it. This distinguishes bronchiolitis from asthma, where smooth-muscle bronchospasm is the primary mechanism.

Back to Table of Contents

Risk Factors for Severe Disease

Most infants with bronchiolitis experience a self-limiting illness managed at home. The following factors predict a higher risk of severe disease, hospitalization, and need for intensive respiratory support:

• Prematurity (<35 weeks gestational age): Underdeveloped airways, surfactant deficiency, and blunted immune responses make premature infants significantly more vulnerable. Risk is highest in the first two respiratory syncytial virus seasons.
• Age <3 months: Narrow airway caliber and obligate nasal breathing make even mild mucosal edema clinically significant. Apnea — sometimes the presenting symptom — is far more common in this age group.
• Congenital heart disease (CHD): Particularly lesions with increased pulmonary blood flow (VSD, AV canal) or those relying on pulmonary vascular resistance balance. Hypoxemia from bronchiolitis is poorly tolerated.
• Chronic lung disease (CLD) / bronchopulmonary dysplasia (BPD): Already-compromised gas exchange reserves leave little margin for additional V/Q mismatch.
• Immunodeficiency: T-cell deficiencies, severe combined immunodeficiency (SCID), DiGeorge syndrome, and transplant immunosuppression allow prolonged viral replication and atypical severe presentations.
• Tobacco smoke exposure: Prenatal and postnatal exposure impairs mucociliary clearance, increases airway inflammation, and roughly doubles the risk of severe respiratory syncytial virus disease.
• Absence of breastfeeding: Breast milk provides secretory immunoglobulin A (IgA), lactoferrin, and anti-inflammatory cytokines that reduce respiratory syncytial virus severity; formula-fed infants have measurably higher hospitalization rates.
• Household crowding and daycare attendance: Increases viral exposure density, particularly for respiratory syncytial virus and rhinovirus.

Back to Table of Contents

Clinical Presentation

Bronchiolitis evolves in a predictable biphasic pattern over 7–14 days:

Upper respiratory prodrome (days 1–3): The illness begins with symptoms indistinguishable from a common cold — rhinorrhea (often copious and clear), mild cough, and low-grade fever (38–38.5°C). Parents frequently report that a sibling or caregiver had a "cold" the week before. Feeding remains mostly normal in this phase.

Lower respiratory phase (days 3–7): Virus descends to the bronchioles and the picture changes rapidly. The cardinal signs are:

• Tachypnea: Respiratory rate above 60 breaths/min in young infants is common and is the most sensitive early sign of lower tract involvement.
• Wheezing: Polyphonic expiratory wheeze from multiple narrowed airways; may be audible without a stethoscope. Crackles (rales) on auscultation reflect airway secretions and atelectasis.
• Retractions: Subcostal and intercostal retractions signal increased work of breathing. Suprasternal and sternal retractions indicate more severe obstruction.
• Nasal flaring: An accessory respiratory muscle sign, particularly prominent in young infants.
• Poor feeding: Increased work of breathing, nasal congestion, and tachypnea disrupt the suck-breathe-swallow sequence, reducing oral intake significantly.

Apnea: In infants under 2 months (especially former premature infants), apnea may be the presenting or predominant sign, occurring before or in the absence of obvious respiratory distress. Central apnea from respiratory syncytial virus has distinct pathophysiology involving brainstem effects of viral neuroinvasion or hypoxia-triggered respiratory inhibition.

Peak and resolution: Symptoms peak on days 3–5. SpO2 naturally nadirs during this period. Feeding difficulty often persists beyond resolution of wheezing. Cough may linger for 2–3 weeks. Most previously healthy infants recover fully within 14 days.

Back to Table of Contents

Severity Assessment

The American Academy of Pediatrics (AAP) and most clinical protocols stratify bronchiolitis severity to guide disposition decisions. Pulse oximetry is the cornerstone of objective assessment.

Mild bronchiolitis:

• SpO2 ≥95% on room air
• Respiratory rate <60 breaths/min
• Mild retractions or none
• Alert and interactive; adequate feeding (≥50% of normal intake)
• No apnea

Moderate bronchiolitis:

• SpO2 90–94% on room air
• Respiratory rate 60–70 breaths/min
• Moderate intercostal or subcostal retractions
• Irritable but consolable; reduced but present oral intake
• No apnea

Severe bronchiolitis:

• SpO2 <90% on room air
• Respiratory rate >70 breaths/min
• Severe retractions; suprasternal or sternal involvement; head bobbing
• Markedly decreased or absent feeding; lethargy or poor responsiveness
• Apnea (any episode)
• Cyanosis

Respiratory distress scoring systems such as the Respiratory Distress Assessment Instrument (RDAI) or the Bronchiolitis Severity Score (BSS) combine auscultatory findings, retractions, and respiratory rate into a composite score. These are research tools more than bedside mandates, but they improve inter-rater reliability and are commonly used in clinical trials.

Apnea as a danger sign: Any documented or witnessed apnea in an infant with bronchiolitis — regardless of current oxygen saturation — warrants hospital admission and cardiorespiratory monitoring. Apnea can be abrupt and silent; it remains one of the leading causes of bronchiolitis-related death.

Back to Table of Contents

Diagnosis

The AAP 2014 Clinical Practice Guideline (with a 2015 erratum) is explicit: bronchiolitis is a clinical diagnosis. The history and physical examination are sufficient in the vast majority of cases, and the guideline actively discourages reflex testing that does not change management.

What the guideline supports:

• Pulse oximetry: Essential for all infants with suspected bronchiolitis. SpO2 is the primary objective parameter guiding oxygen therapy, admission, and discharge decisions.
• History and examination: Age, gestational age, risk factors, feeding intake, apnea episodes, and careful auscultation (wheeze, crackles, air entry) drive management decisions more reliably than any test.
• Why oximetry readings get careful handling: In a trial of 213 infants with mild to moderate bronchiolitis (Schuh et al., JAMA 2014), 41% were admitted within 72 hours when doctors saw true oximeter readings and 25% when they saw artificially raised readings, with no significant difference in unscheduled return visits (21.3% vs. 14.3%). The authors conclude the reading "should not be the only factor in the decision to admit."

What the guideline does not support as routine:

• Viral testing (respiratory syncytial virus, influenza, respiratory panel): The AAP guideline recommends against routine viral testing because it rarely changes management. A positive respiratory syncytial virus test does not alter treatment; a negative result does not exclude bronchiolitis from another virus. Exception: cohorting of hospitalized patients to reduce nosocomial spread may justify respiratory syncytial virus rapid testing in an inpatient setting.
• Chest radiography (CXR): Routine CXR is not recommended. Radiographic findings in bronchiolitis (peribronchial thickening, hyperinflation, patchy infiltrates from atelectasis) are nonspecific and frequently misinterpreted as pneumonia, leading to unnecessary antibiotic prescriptions. CXR is indicated when the diagnosis is uncertain (e.g., unilateral findings, suspected foreign body, clinical deterioration), in severe disease requiring intensive care, or when a complication such as pneumothorax is suspected.
• Complete blood count (CBC): A normal or mildly elevated white cell count does not exclude secondary bacterial infection, and an elevated count does not confirm it. Complete blood count is not part of routine bronchiolitis evaluation.
• Blood cultures and lumbar puncture: Reserved for infants who appear septic, are under 1 month of age, or have an unusually toxic presentation suggesting bacterial co-infection.

Back to Table of Contents

Treatment — Supportive Care

Supportive care is the cornerstone and only evidence-based treatment for bronchiolitis. No pharmacologic intervention has demonstrated consistent benefit in unselected infants with bronchiolitis. The goals are to maintain oxygenation, preserve hydration, reduce work of breathing, and allow the natural viral illness to resolve.

Supplemental oxygen:

• Indicated when SpO2 falls below 90–92% on room air. The AAP 2014 guideline uses a threshold of 90%; many centers use 92% to allow a safety margin and reduce the frequency of desaturations triggering nursing interventions.
• Delivery method escalates from nasal cannula (low-flow) → high-flow nasal cannula → CPAP → mechanical ventilation depending on severity.
• Continuous SpO2 monitoring is appropriate in admitted infants; intermittent monitoring is sufficient once the infant is clinically stable and feeding well.

Nasal suctioning:

• Bulb syringe or wall-suction nasal suctioning to clear secretions before feeding and as needed for comfort.
• Nasopharyngeal (deep) suctioning temporarily relieves obstruction in mechanically ventilated or HFNC patients but causes transient desaturation; it is generally reserved for clinical need rather than a routine schedule.
• Saline drops before suctioning loosen thick secretions and may improve feeding tolerance.

Hydration:

• Adequate hydration maintains mucociliary function and prevents dehydration from reduced oral intake and increased insensible losses from tachypnea.
• Oral or nasogastric (NG) feeding is preferred over intravenous (IV) fluids when safely tolerated, as it avoids the risks of peripheral intravenous insertion and hyponatremia from excessive hypotonic intravenous fluids.
• Intravenous fluids (isotonic saline-based solutions) are indicated when respiratory rate exceeds 60–70 breaths/min (making safe swallowing impossible) or when the infant is significantly dehydrated.

Positioning and environment:

• Head-of-bed elevation at 30° reduces aspiration risk and may slightly reduce work of breathing, though evidence is limited.
• A calm, low-stimulation environment reduces crying — which dramatically worsens V/Q mismatch — and lowers oxygen demand.
• Clustering of nursing care (vital signs, assessments, suctioning) minimizes disturbance intervals.

Back to Table of Contents

Treatment — High-Flow Nasal Cannula

High-flow nasal cannula (HFNC) therapy has become the standard of care for moderate-to-severe bronchiolitis that fails conventional low-flow oxygen. It represents the most significant advance in bronchiolitis management of the past two decades.

How HFNC works:

• Flushing nasopharyngeal dead space: High gas flows wash out CO2 that accumulates in the nasopharynx, reducing rebreathing and improving effective alveolar ventilation.
• Positive distending pressure: Flows exceeding the infant's peak inspiratory flow generate a small but consistent positive end-expiratory pressure (PEEP, typically 2–5 cmH2O), stenting open edematous bronchioles and recruiting atelectatic alveoli.
• Heated humidification: Gas is warmed to 37°C and humidified to 100% relative humidity, preventing cold-dry gas-induced mucosal injury and reducing metabolic cost of airway humidification.
• Reduction in work of breathing: By reducing resistive and elastic work, HFNC decreases respiratory rate, retractions, and accessory muscle use within 1–4 hours of initiation in most responders.

Dosing and initiation:

• Standard starting flow: 2 L/kg/min (commonly capped at 20–25 L/min in larger infants).
• FiO2 is titrated to maintain SpO2 ≥92–95%.
• An appropriately sized cannula occludes no more than 50% of the naris to allow pressure equilibration and prevent inadvertent excessive PEEP.

Evidence base:

• The 2024 Cochrane review of 16 trials and 2,813 infants (Armarego et al., PMID 38506440) found that high-flow oxygen compared with low-flow probably lowers treatment escalation, a defined step up in care (risk ratio 0.55, moderate certainty), and probably improves breathing and heart rates. It may also shorten hospital stay by 0.65 days and oxygen use by 0.59 days, both at low certainty.
• On intubation, a single-center chart review from Australia (Schibler et al., 2011, PMID 21369809) reports that intubation in infants with viral bronchiolitis fell from 37% to 7% as high-flow use rose; this was observational, with no comparison group.
• The PARIS trial (Franklin et al., NEJM 2018, PMID 29562151) — the largest bronchiolitis HFNC RCT — found that early HFNC in infants treated outside an intensive care unit reduced escalation of care due to treatment failure by 50% compared with standard low-flow oxygen (12% vs. 23%). No significant differences were observed in the duration of hospital stay or of oxygen therapy.
• HFNC is now widely considered standard of care for moderate-to-severe bronchiolitis at centers with PICU backup. It is initiated in the emergency department or general pediatric ward and allows many infants to avoid PICU transfer.

Failure criteria and escalation:

• Failure to improve within 1–2 hours of HFNC at adequate flow and FiO2 is a common trigger for considering CPAP, non-invasive positive pressure ventilation (NIPPV), or intubation.
• HFNC does not negate the need for close monitoring; deterioration can be sudden, particularly with apnea.

Back to Table of Contents

What Does NOT Work

Evidence-based medicine in bronchiolitis is largely a story of negative trials. Decades of rigorously conducted randomized controlled trials (RCTs) have failed to demonstrate benefit from interventions that remain intuitively attractive or are widely requested by parents. The AAP guideline reflects this evidence by issuing strong recommendations against several common treatments.

Albuterol (and other beta-2 agonists):

• The AAP recommends clinicians should not administer albuterol (salbutamol) or other beta-2 agonists to infants with bronchiolitis (strong recommendation, Grade A evidence).
• Rationale: Airway obstruction in bronchiolitis is mechanical (debris, edema, cellular necrosis), not bronchospasm. There is no smooth-muscle component to relax.
• Multiple placebo-controlled trials show no reduction in hospitalization rate, length of stay, or symptom duration; the 2014 Cochrane review of 30 trials and 1,992 infants (Gadomski and Scribani, PMID 24937099) found no reduction in outpatient hospitalization or in the duration of inpatient hospitalization. Transient perceived improvements on clinical scoring may represent arousal effects of aerosol administration.

Racemic epinephrine:

• While nebulized epinephrine produces short-term (30–60 min) improvements in clinical scores through vasoconstriction and brief bronchodilation, the 2011 Cochrane review (Hartling et al.) found that, compared with placebo among outpatients, it reduced admissions at Day 1 (risk ratio 0.67) but not at Day 7, and that it made no difference to length of stay among inpatients.
• A landmark NEJM 2009 randomized controlled trial (Plint et al., PMID 19439742) and Cochrane meta-analysis (Hartling et al., 2011, PMID 21678340) report no sustained benefit from epinephrine alone.
• The rebound effect after epinephrine wears off means infants who appear improved at 2 hours may deteriorate upon return home — a safety concern that makes outpatient epinephrine use problematic.

Systemic corticosteroids (dexamethasone, prednisolone):

• Multiple large randomized controlled trials and subsequent Cochrane reviews (Fernandes et al., 2013, PMID 23733383) show no benefit of systemic steroids given alone for bronchiolitis hospitalization rate (risk ratios 0.92 at day 1 and 0.86 at day 7, not significant), length of stay, or symptom duration.
• The combination is a separate finding. In the Plint et al. trial, by day 7, 17.1% of infants given dexamethasone plus epinephrine had been admitted against 26.4% on placebo (relative risk 0.65, P=0.02, which became P=0.07 after adjusting for multiple comparisons). The authors conclude the combination "may significantly reduce hospital admissions"; the Cochrane review calls the result exploratory, with limited safety data.
• The AAP recommends clinicians should not administer systemic corticosteroids to infants with bronchiolitis in any setting (strong recommendation, Grade A evidence).
• This differs from croup and from true asthma exacerbations, where steroids are first-line. Bronchiolitis is not asthma — the two conditions are mechanistically distinct.

Inhaled hypertonic saline:

• Initial trials suggested benefit in hospitalized infants; however, later trials did not confirm it. In the emergency department, Florin et al. (JAMA Pediatrics 2014, PMID 24862342) found no significant difference in hospitalization and less score improvement with hypertonic saline, and Angoulvant et al. (JAMA Pediatrics 2017, PMID 28586918) found no significant reduction in admissions among 777 infants (48.1% vs. 52.2%). In infants already hospitalized, the SABRE trial (Everard et al., Thorax 2014, PMID 25389139) found no difference in time to discharge. The AAP guideline does not recommend hypertonic saline for the ED setting but allows for its use in hospitalized patients, where the evidence is mixed.

Ribavirin:

• The antiviral ribavirin has theoretical activity against respiratory syncytial virus but is not recommended for routine bronchiolitis given poor clinical efficacy, high cost, significant toxicity, and difficult administration (inhaled). Its use is limited to severely immunocompromised patients in consultation with specialists.

Antibiotics:

• Bronchiolitis is a viral disease. Antibiotics have no role unless a secondary bacterial infection (pneumonia, otitis media, urinary tract infection) is specifically identified. Secondary bacterial pneumonia complicating bronchiolitis is uncommon. Reflexive antibiotic prescribing contributes to antimicrobial resistance without clinical benefit.

Back to Table of Contents

Indications for Hospitalization

The decision to admit reflects a gestalt of oxygen saturation, work of breathing, hydration status, age, risk factors, and parental ability to monitor and return quickly. The following are evidence-based criteria:

Definitive indications:

• SpO2 <90–92% on room air that requires supplemental oxygen to maintain; the infant cannot be safely weaned to room air in the emergency department.
• Apnea — any witnessed or documented apneic episode, regardless of current SpO2.
• Severe respiratory distress — respiratory rate >70/min, significant retractions, head bobbing, grunting, inability to maintain oxygenation despite supplemental oxygen.
• Dehydration — inability to tolerate sufficient oral intake (typically defined as <50% of usual intake), signs of dehydration, or need for intravenous or nasogastric hydration.

High-risk patient characteristics that lower the threshold:

• Age <2 months (corrected gestational age preferred for premature infants)
• Gestational age <35 weeks at birth in first 2 respiratory syncytial virus seasons
• Congenital heart disease (especially hemodynamically significant)
• Chronic lung disease / BPD
• Immunodeficiency or active immunosuppression
• Neuromuscular disease impairing respiratory reserve
• Social factors: distant home, limited transport, parental inability to recognize deterioration or return promptly

Discharge criteria:

• SpO2 ≥90–92% on room air consistently for 4–6 hours (not just transiently between feeds)
• Adequate oral hydration maintained without assistance
• Respiratory distress resolved or mild and stable
• No apnea in preceding observation period
• Parents/caregivers comfortable with monitoring and have explicit return precautions

Back to Table of Contents

Prevention

Respiratory syncytial virus-specific prevention has been transformed since 2023 by the U.S. Food and Drug Administration (FDA) approval of nirsevimab, a long-acting monoclonal antibody that provides passive immunity through an entire respiratory syncytial virus season from a single intramuscular injection.

Nirsevimab:

• Mechanism: A recombinant IgG1 monoclonal antibody with half-life-extended Fc modifications (YTE mutations), targeting the respiratory syncytial virus prefusion F protein. Unlike older antibodies, its engineered half-life (~70 days) enables a single-dose seasonal strategy.
• Efficacy: The MELODY trial (U.S. Food and Drug Administration pivotal trial) demonstrated 74.5% reduction in medically attended respiratory syncytial virus lower respiratory tract disease versus placebo. Its own figure for hospitalization was 62.1%, which was not statistically significant (95% confidence interval −8.6 to 86.8; P=0.07). The 77.3% reduction in respiratory syncytial virus-associated hospitalization comes from the pooled analysis of the phase 2b trial and MELODY (Simões et al., 2023, PMID 36634694). The HARMONIE open-label trial (Drysdale et al., NEJM 2023, PMID 38157500) showed 83.2% reduction in respiratory syncytial virus-associated hospitalization.
• Dosing: Single IM injection: 50 mg for infants <5 kg; 100 mg for infants ≥5 kg.
• Recommendation: The U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommends nirsevimab for all infants aged under 8 months who are born during or entering their first respiratory syncytial virus season (October through the end of March in most of the continental United States), and for infants and children aged 8–19 months at increased risk who are entering their second season. The FDA label's wording for the second season is children up to 24 months of age who remain vulnerable to severe disease.
• Real-world results: The French ENVIE study (Assad et al., NEJM 2024, PMID 38986058) estimated nirsevimab 83.0% effective against hospitalization for respiratory syncytial virus bronchiolitis, 69.6% against critical care and 67.2% against ventilation support. A 2026 meta-analysis of 11 studies, with 236,764 infants and children given nirsevimab (Sumsuzzman et al., PMID 41428293), found lower odds of lower respiratory hospitalization from any cause (odds ratio 0.38) and no significant difference in hospitalization for all causes (odds ratio 0.56, 95% confidence interval 0.14–2.20).
• Safety: Comparable safety profile to placebo in trials; most common adverse events were injection-site reactions. No significant safety signals in post-market surveillance through 2024.

Clesrovimab:

• A second long-acting antibody, given as one fixed 105 mg injection whatever the baby's weight (FDA label; Wiedenmann et al., PMID 42690248). In the trial of 3,614 healthy infants (Zar et al., NEJM 2025, PMID 40961446), efficacy through 150 days was 60.4% against respiratory syncytial virus lower respiratory infection needing medical care and 84.2% against respiratory syncytial virus hospitalization, with serious adverse events in 11.5% vs. 12.4% on placebo.

Maternal respiratory syncytial virus vaccine:

• U.S. Food and Drug Administration approved in 2023 for pregnant individuals at 32–36 weeks gestation. The bivalent prefusion F protein subunit vaccine achieves 82% efficacy against severe respiratory syncytial virus lower respiratory illness in infants through the first 90 days of life via transplacental antibody transfer, falling to 69.4% by 180 days (Kampmann et al., PMID 37018474). ACIP and CDC state that either maternal vaccination or nirsevimab is recommended, "but both are not needed for most infants," with vaccination given September through the end of January in most of the continental United States (PMID 37824423).

Palivizumab — for high-risk infants in second season:

• Palivizumab remains indicated for high-risk infants (premature <29 weeks, hemodynamically significant CHD, CLD) who are entering their second respiratory syncytial virus season. It requires monthly IM injections (15 mg/kg) for up to 5 doses per season. The AAP Committee on Infectious Diseases updates eligibility criteria annually; eligibility narrowed in 2014 but expanded slightly for certain populations.

Non-pharmacologic prevention:

• Hand hygiene: The most effective intervention for interrupting viral transmission in household and healthcare settings.
• Breastfeeding: Associated with 36–56% reduction in respiratory syncytial virus hospitalization risk; secretory immunoglobulin A and other immune mediators in breast milk provide local mucosal protection.
• Tobacco smoke avoidance: Eliminates a major modifiable risk factor for severity.
• Cohort isolation: respiratory syncytial virus-positive hospitalized infants are commonly cohorted or placed in contact precautions to prevent nosocomial spread.

Back to Table of Contents

Key Research Papers

The following citations represent landmark studies and current guidelines informing bronchiolitis management:

1. Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474–e1502. — PubMed PMID: 25349312
2. Franklin D, Babl FE, Schlapbach LJ, et al. A randomized trial of high-flow oxygen therapy in infants with bronchiolitis. N Engl J Med. 2018;378(12):1121–1131. — PubMed PMID: 29562151
3. Schuh S, Freedman S, Coates A, et al. Effect of oximetry on hospitalization in bronchiolitis: a randomized clinical trial. JAMA. 2014;312(7):712–718. — PubMed PMID: 25138332
4. Plint AC, Johnson DW, Patel H, et al. Epinephrine and dexamethasone in children with bronchiolitis. N Engl J Med. 2009;360(20):2079–2089. — PubMed PMID: 19439742
5. Hartling L, Bialy LM, Vandermeer B, et al. Epinephrine for bronchiolitis. Cochrane Database Syst Rev. 2011;(6):CD003123. — PubMed PMID: 21678340
6. Fernandes RM, Bialy LM, Vandermeer B, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev. 2013;(6):CD004878. — PubMed PMID: 23733383
7. Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415–425. — PubMed PMID: 32726528
8. Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants (MELODY trial). N Engl J Med. 2022;386(9):837–846. — PubMed PMID: 35235726
9. Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev. 2014;35(12):519–530. — PubMed PMID: 25452661
10. Zorc JJ, Hall CB. Bronchiolitis: recent evidence on diagnosis and management. Pediatrics. 2010;125(2):342–349. — PubMed PMID: 20100768
11. Milési C, Matecki S, Jaber S, et al. 6 cmH2O continuous positive airway pressure versus conventional oxygen therapy in severe viral bronchiolitis. Pediatr Pulmonol. 2013;48(1):45–51. — PubMed PMID: 22431446
12. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344(25):1917–1928. — PubMed PMID: 11419430
13. Hasegawa K, Tsugawa Y, Brown DF, et al. Trends in bronchiolitis hospitalizations in the United States, 2000-2009. Pediatrics. 2013;132(1):28–36. — PubMed PMID: 23733801
14. Fujiogi M, Goto T, Yasunaga H, et al. Trends in bronchiolitis hospitalizations in the United States: 2000-2016. Pediatrics. 2019;144(6):e20192614. — PubMed PMID: 31699829
15. Tripp RA, Jones LP, Haynes LM, et al. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol. 2001;2(8):732–738. — PubMed PMID: 11477410
16. Johnson SM, McNally BA, Ioannidis I, et al. Respiratory syncytial virus uses CX3CR1 as a receptor on primary human airway epithelial cultures. PLoS Pathog. 2015;11(12):e1005318. — PubMed PMID: 26658574
17. Armarego M, Forde H, Wills K, Beggs SA. High-flow nasal cannula therapy for infants with bronchiolitis. Cochrane Database Syst Rev. 2024;3(3):CD009609. — PubMed PMID: 38506440
18. Schibler A, Pham TM, Dunster KR, et al. Reduced intubation rates for infants after introduction of high-flow nasal prong oxygen delivery. Intensive Care Med. 2011;37(5):847–852. — PubMed PMID: 21369809
19. Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2014;(6):CD001266. — PubMed PMID: 24937099
20. Florin TA, Shaw KN, Kittick M, et al. Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial. JAMA Pediatr. 2014;168(7):664–670. — PubMed PMID: 24862342
21. Everard ML, Hind D, Ugonna K, et al. SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. Thorax. 2014;69(12):1105–1112. — PubMed PMID: 25389139
22. Angoulvant F, Bellêttre X, Milcent K, et al. Effect of nebulized hypertonic saline treatment in emergency departments on the hospitalization rate for acute bronchiolitis: a randomized clinical trial. JAMA Pediatr. 2017;171(8):e171333. — PubMed PMID: 28586918
23. Simões EAF, Madhi SA, Muller WJ, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7(3):180–189. — PubMed PMID: 36634694
24. Drysdale SB, Cathie K, Flamein F, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389(26):2425–2435. — PubMed PMID: 38157500
25. Assad Z, Romain AS, Aupiais C, et al. Nirsevimab and hospitalization for RSV bronchiolitis. N Engl J Med. 2024;391(2):144–154. — PubMed PMID: 38986058
26. Sumsuzzman DM, Shi C, Langley JM, Moghadas SM. Nirsevimab against hospitalizations and emergency department visits for lower respiratory tract infection in infants: a meta-analysis. JAMA Pediatr. 2026;180(2):152–159. — PubMed PMID: 41428293
27. Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(34):920–925. — PubMed PMID: 37616235
28. Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(41):1115–1122. — PubMed PMID: 37824423
29. Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451–1464. — PubMed PMID: 37018474
30. Zar HJ, Simões EAF, Madhi SA, et al. Clesrovimab for prevention of RSV disease in healthy infants. N Engl J Med. 2025;393(13):1292–1303. — PubMed PMID: 40961446
31. Wiedenmann M, Dangor Z, Madhi SA. Clesrovimab, a monoclonal antibody for the prevention of respiratory syncytial virus disease in infants: a drug profile. Expert Rev Respir Med. 2026;20(11):1263–1275. — PubMed PMID: 42690248

Search PubMed: bronchiolitis infant treatment  |  Search PubMed: bronchiolitis high-flow nasal cannula  |  Search PubMed: nirsevimab Respiratory Syncytial Virus prevention

Back to Table of Contents

Connections

• Pediatrics
• Respiratory Syncytial Virus Bronchiolitis
• Croup
• Febrile Seizures
• Neonatal Jaundice
• Respiratory Syncytial Virus
• Asthma
• Pneumonia

Featured Videos